In the PANGEA trial of personalized antibodies for gastroesophageal patients, profiling of both primary and metastatic tumor tissue specimens led to treatment reassignment in almost a third of patients, many of which had HER2-positive metastases (14). Here, ERBB2 is linked to metastatic neoplasm.